如何高效查询MedSci期刊数据库系统?

2021-02-21 MedSci原创 MedSci原创

MedSci期刊数据库目前收录期刊13500余种,仍然在不断更新。这里介绍如何更好地使用与查询:

MedSci期刊数据库目前收录期刊13500余种,仍然在不断更新。这里介绍如何更好地使用与查询:

一、MedSci期刊数据库有哪些功能?

1、搜索期刊:可以用中文,英文,简称,全称,ISSN号进行相关搜索,均可以得到您想要的结果。这是目前较为方便的数据库查询。例如,您对该领域的期刊并不熟悉,可以用一些模糊的学科搜索:如癌症,肿瘤,细胞,分子,药理等。如果对指定期刊很熟悉,则用全称更好。当然,一些业内公认的简称,如JBC,JCB,CMJ,NEJM等,都可以直接搜索。

2、为每个期刊提供全面详细的信息

特色在于影响指数与热门指数,以及论坛。影响指数主要提供JIF(期刊影响指数)和citescore,H指数,对于目前的所谓的影响因子,因为它是收费系统,因此,并不推荐使用。期刊影响指数与传统的影响因子相比,更为精准与客观,能更好地反映一个期刊的真实的影响水平。citescore是elsevier旗下的期刊评价系统,收录杂志范围高达23000余种,数量偏多,因此,一些低质量期刊也被纳入体系。

热门指数指的是中国学者关注的期刊,主要目的帮助大家更好地选择期刊进行投稿,同时识别水刊,以及期刊的异动(如果期刊突然热门指数上升,表明可能有异动。例如当年Medicine出现灌水,MedSci数据库是第一个发现,影响因子从8分直接降至3分以内,后来直线到达1-2分)。当然,也能很快发现期刊影响可能上升的情况。

期刊论坛:可以进行交流,提问,期刊各类动态都应该能及时了解到。论坛可以参与,回复等。同时在论坛中很多网友贡献了影响因子,审稿周期,关键词等有用的信息,也可以拿来使用。

二、期刊搜索列表页

所有红色标出的,其实都是十分有用的功能哦

三、期刊内容页

所有标出的红色的,都是有用的链接,不能忽视哦。

 

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-06-02 剑中波

    明白了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-04-14 梅干儿

    三人行,必有我师。 #梅斯医学科研互助群# 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-22 ms7000000254193164

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-22 走,走走

    标记

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-22 rabiby

    很受用

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-22 rabiby

    很受启发

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 1435a51cm08暂无昵称

    很收益,有收获,谢谢

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=970367, encodeId=8a2b9e0367de, content=明白了, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XUzvuoBCNx3qLvUSCQiatoxuhokNmFB1HKtL1iba6HwxcmljqG1pCYnSEquqHSTR8TyC3tb81qhib27vYM0wv2Ymw/132, createdBy=27232556793, createdName=剑中波, createdTime=Wed Jun 02 15:57:45 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957011, encodeId=305395e011da, content=三人行,必有我师。 <a href='/topic/show?id=d55f104233bd' target=_blank style='color:#2F92EE;'>#梅斯医学科研互助群#</a> 欢迎您的加入,添加【梅斯医学科研助手WeChat:medsci_2021】邀您进群! 【社群简介】👉 梅斯医学目前已建立覆盖肿瘤、心血管、神经、消化、内分泌、呼吸等30个科室的学习交流社群。 【入群福利】👉 群内可实时交流病例,提问同行,跨群讨论,每天更新前沿医学资讯和指南共识,每周推出至少1场专业直播,不时共享科研干货,入群即可获得100份SCI写作攻略!, beContent=null, objectType=article, channel=null, level=null, likeNumber=627, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104233, encryptionId=d55f104233bd, topicName=梅斯医学科研互助群)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:47 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=957010, encodeId=be0c95e01017, content=👇👇👇【社群入口】移动端用户可点击图片长按保存,到WeChat打开扫描入群!, beContent=null, objectType=article, channel=null, level=null, likeNumber=652, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=[AttachmentDto(url=https://img.medsci.cn/comment/20210414/f7d292d5387b41aea2be84881c8731eb.png, type=image, width=464, height=464)], authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210413/08ec7710e47c4f6dba6c277207bf00ec/823f09e953ea44188e56b38cd2f16334.jpg, createdBy=ec565230154, createdName=梅干儿, createdTime=Wed Apr 14 18:27:38 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610912, encodeId=d2e1161091228, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=220, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Feb 23 10:49:38 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926334, encodeId=73679263340d, content=可, beContent=null, objectType=article, channel=null, level=null, likeNumber=664, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549b5398500, createdName=ms7000000254193164, createdTime=Mon Feb 22 12:19:47 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926318, encodeId=fd1592631857, content=标记, beContent=null, objectType=article, channel=null, level=null, likeNumber=493, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Feb 22 10:49:26 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926272, encodeId=88049262e278, content=很受用, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:46 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926271, encodeId=b7469262e143, content=很受启发, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93221414867, createdName=rabiby, createdTime=Mon Feb 22 05:49:21 CST 2021, time=2021-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926234, encodeId=477a926234aa, content=很收益,有收获,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1064781784, createdName=1435a51cm08暂无昵称, createdTime=Sun Feb 21 21:47:45 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926218, encodeId=5037926218ce, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=712d5461304, createdName=ms2000002063028856, createdTime=Sun Feb 21 20:59:32 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 ms2000002063028856

    了解

    0